This content is unpublished, click the edit tab and check "Published" on the bottom of the form.
09.
10.15
16:25
Close share menu
KEYTRUDA (Pembrolizumab) for first-line treatment of advanced melanoma receives new draft of the recommendation by the National Institute for health and care Excellence (NICE) in the United Kingdom